Carillon Tower Advisers, an investment management firm, published its fourth quarter 2020 “Carillon Eagle Small Cap Growth Fund” investor letter – a copy of which can be downloaded here. In the letter, the fund talked about their best and worst securities, together with their outlook for this year from an investment perspective. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Carillon Eagle Small Cap Growth Fund, in their Q4 2020 investor letter, mentioned Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) and emphasized their views on the company. Horizon Therapeutics Public Limited Company is a Dublin 4-based biopharmaceutical company that currently has an $18.71 billion market capitalization. Since the beginning of the year, HZNP delivered a 14.09% return, impressively extending its 12-month gains to 193.87%. As of March 24, 2021, the stock closed at $82.12 per share.
Here is what Carillon Eagle Small Cap Growth Fund has to say about Horizon Therapeutics Public Limited Company in their Q4 2020 investor letter:
“Horizon Therapeutics operates as a biopharmaceutical company whose primary focus is research, development, and marketing of late-stage pharmaceutical products. The firm is currently experiencing some unfortunate short-term manufacturing issues for their key product, Tepezza, which is used in the treatment of thyroid eye disease. These issues are directly associated to the COVID-19 vaccine production orders related to Operation Warp Speed.”
Our calculations show that Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) does not belong in our list of the 30 Most Popular Stocks Among Hedge Funds. As of the end of the fourth quarter of 2020, Horizon Therapeutics Public Limited Company was in 55 hedge fund portfolios, compared to 61 funds in the third quarter. EBS delivered a 20.21% return in the past 3 months.